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Practice Points 13 
 Exercise, behavioural interventions, and rehabilitation demonstrate potential to manage 14 
fatigue in progressive MS populations.  15 
 Evidence in this review suggests that aerobic exercise can improve fatigue in people with 16 
progressive MS; however, the optimal dose was not determined. 17 
 Further evidence is required to determine the effectiveness of these interventions in 18 
studies that use fatigue as the primary outcome and recruit people who are experiencing 19 
high levels of fatigue. 20 




Background: Rehabilitation interventions are recommended to manage Multiple Sclerosis 23 
(MS) related fatigue. However, existing research has largely been generalised to those with 24 
relapsing-remitting MS, making it difficult to determine the effectiveness of these 25 
interventions amongst people with progressive MS. Therefore, this study aimed to 26 
systematically review the evidence related to the effectiveness of fatigue management 27 
interventions in reducing the severity and/or impact of fatigue in people with progressive MS. 28 
Methods: Six electronic databases (CINAHL, Cochrane Library, MEDLINE, PEDro, 29 
ProQuest, and Web of Science Core Collections) were searched for relevant articles up until 30 
November 2017.  Randomised controlled trials and quasi-experimental studies that examined 31 
the effects of exercise, behavioural interventions, and rehabilitation on fatigue in people with 32 
progressive MS using self-reported fatigue outcome measures were included in this review.  33 
Results: Eight exercise, two rehabilitation and two behavioural interventions were 34 
investigated by the 13 articles included in this review. Heterogeneous effects were reported 35 
between studies with only two exercise, one behavioural, and two rehabilitation interventions 36 
recording significant improvements in fatigue severity or impact post-intervention. However, 37 
most studies were underpowered, only two studies used fatigue as the primary outcome, and 38 
only one specifically recruited participants with pre-defined levels of fatigue. 39 
Conclusion: Evidence from this review is inconclusive regarding the effectiveness of non-40 
pharmacological interventions in reducing the impact and severity of fatigue in progressive 41 
MS populations. Adequately powered randomised controlled trials are required to evaluate 42 
fatigue management interventions in people with progressive MS experiencing high levels of 43 
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Fatigue is a common symptom of Multiple Sclerosis (MS) reported in over 70% of the 55 
population.
1-3
 MS-related fatigue is often perceived as the most debilitating symptom, which 56 
significantly impacts upon activities of daily living, social participation and quality of life,
 4-5
  57 
and is associated with changes to employment.
6
 Fatigue is a highly complex and 58 
multifactorial symptom that may be defined as “a subjective lack of physical and/or mental 59 
energy that is perceived by the individual or caregiver to interfere with usual and desired 60 
activities”.7 Subjectively, this may be described as exhaustion, a lack of energy, or 61 
overwhelming tiredness which is pervasive and can occur at rest.
8
  62 
Although fatigue can be experienced throughout the course of MS, it has a higher 63 
prevalence amongst people with progressive forms of the disease.
1, 9-10
 Primary pathological 64 
disease processes involving structural and functional central nervous system (CNS) changes, 65 
and secondary factors independent of MS pathology are associated with fatigue 66 
pathogenesis.
11-13
 However, as the pathophysiological mechanisms underlying fatigue in MS 67 
are not well understood,
11-13
 current treatment strategies are focused on symptom 68 
management through non-pharmacological interventions.
14 
69 
Rehabilitation interventions are recommended to manage MS-related fatigue,
14
 and 70 
several studies have demonstrated that interventions such as exercise, energy conservation 71 
management, and cognitive behavioural therapy have moderate, positive short-term effects on 72 
fatigue outcomes.
15-18
 However, results have largely been generalised to those with relapsing 73 
remitting MS (RRMS), with few studies making a distinction between RRMS and 74 
progressive MS populations. Therefore, in line with The International Progressive MS 75 
Alliance research priorities,
19
 there is a need to determine the effectiveness of fatigue 76 
management interventions in people with progressive MS due to the high prevalence and 77 
impact of fatigue amongst this population. Hence, the aim of this work was to systematically 78 
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review the evidence related to the effectiveness of fatigue management interventions in 79 
reducing the severity and/or impact of fatigue in people with progressive MS. To achieve this 80 
aim the following objectives were met: (i) to summarise the details of fatigue management 81 
interventions for people with progressive MS; (ii) to critically evaluate the effectiveness of 82 
fatigue management interventions in reducing the severity and/or impact of fatigue in people 83 
with progressive MS; (iii) to identify limitations of the current evidence to inform the 84 
direction of future study.  85 
 86 
Methods 87 
Systematic review protocol and registration  88 
A review protocol was developed and registered with the PROSPERO database in 89 
December 2017 (PROSPERO ID: CRD42017082203).  90 
 91 
Search Strategy  92 
Searches of the following databases were conducted from inception to November 93 
2017: CINAHL (via EBSCOhost), Cochrane Library, MEDLINE (via Ovid), PEDro, 94 
ProQuest (Health & Medical Collection, Nursing & Allied Health Database, PsycINFO), and 95 
Web of Science Core Collections. Search strategies included a combination of keywords and 96 
subject headings related to multiple sclerosis, exercise, behavioural therapy, rehabilitation 97 
and fatigue, and were adapted for use in each different database (Supplementary table 1). 98 
Reference lists of relevant review articles were also hand searched to identify any additional 99 
articles. After each database was searched, results were exported to Covidence systematic 100 
review software (2017, Veritas Health Innovation, Melbourne, Australia) and duplicates were 101 
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removed prior to screening.  The primary reviewer (SR) initially screened all articles by title 102 
and then by abstract against the inclusion and exclusion criteria. Subsequently, two reviewers 103 
(SR and LP) independently screened full texts of the remaining articles for eligibility. 104 
Disagreements were resolved through consensus in consultation with a third reviewer (FM) if 105 
required. 106 
 107 
Inclusion and exclusion criteria  108 
To be included in this review studies had to have: (i) recruited adults with a definite 109 
diagnosis of MS and a progressive form of the disease (secondary or primary progressive); 110 
(ii) evaluated non-pharmacological interventions in accordance with the definitions provided 111 
in Table 1; (iii) used a self -reported measure of fatigue impact or severity as either a primary 112 
or secondary outcome (including sub-scales of questionnaires); (iv) used a randomised 113 
controlled trial or quasi-experimental design; (v) been published in English. Studies that 114 
included a combination of types of MS were only included when specific results for those 115 
with progressive MS could be identified. Non-human studies, pharmacological studies, and 116 
conference proceedings and abstracts were excluded from this review.  117 
 118 
Table 1 Near here 119 
 120 
Data extraction  121 
Data extraction was completed independently by one reviewer (SR) using a 122 
standardised data extraction form. The data extraction form was developed based on the 123 
CONSORT and TIDieR guidelines.
22-23




Quality assessment  126 
Quality of evidence was assessed using the Downs and Black checklist – a 32- point 127 
scale developed for quality assessment of both randomised controlled trials (RCTs) and non-128 
RCTs.
24-25
 An initial quality assessment was conducted where each of the three reviewers 129 
independently scored an article to ensure consistency in assessment between reviewers. 130 
Following this quality assessment, question 27 of the checklist was modified such that an 131 
article was assigned 1 point for including a sample size calculation and zero if the article did 132 
not, resulting in a total possible score of 28. This modification was implemented in keeping 133 
with two systematic reviews of exercise interventions in MS.
26-27
 Quality assessment was 134 
completed independently by two reviewers. When discrepancy arose, agreement was reached 135 
through consensus in consultation with a third reviewer.  136 
 137 
Data synthesis  138 
Due to the inclusion of quasi-experimental studies and heterogeneity in study design, 139 
it was not feasible to conduct a meta-analysis; therefore, results were generated through 140 
narrative synthesis. Preliminary synthesis involved a descriptive summary of key information 141 
extracted from all articles. Individual study estimates of treatment effects were presented 142 
under each mode of intervention and explored within and between studies considering 143 
moderator variables to explain differences in results. Where available, results for the relevant 144 






Results of the search  149 
Through searching the selected electronic databases, 560 articles were identified, and 150 
an additional 4 articles were added from references lists of relevant studies (Figure 1). After 151 
removing duplicates, 463 articles remained for title and abstract screening of which 308 were 152 
excluded by title and 97 by abstract. The remaining 58 articles were included for full-text 153 
screening. After screening full-texts, 45 articles were excluded as the results of those with 154 
progressive MS were not identifiable in 41 studies (either MS type was not reported, or 155 
results for those with progressive MS were not presented separately), 3 studies did not 156 
include participants with progressive MS, and 1 study did not include a fatigue outcome 157 
measure. Two articles described the same study but reported different outcome measures;
29-30
 158 
therefore, 13 articles from 12 studies were included (Table 2).  159 
 160 
Figure 1 Near here 161 
 162 
Table 2 Near here 163 
 164 
Study design  165 
From the included articles, six were RCTs,
31-32, 36-37, 39, 41
 and seven were quasi-166 
experimental studies (pre/post-test design (n=4),
34-35, 38, 40
 non-randomised controlled trial 167 
design (n=2),
29-30
 and non-randomised cross-over trial design (n=1)
33
). All but one RCT 168 
included two trial arms (control and intervention) – the study by Briken et al involved three 169 
intervention conditions in addition to the control group.
36
 The length of intervention period 170 
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ranged from 4-52 weeks; however, most studies delivered interventions for ≤ 12 weeks 171 
(n=11), with one rehabilitation intervention lasting 52 weeks.
29-30
 Four articles reported 172 




 or eight weeks post-173 
intervention.
33
  174 
 175 
Quality assessment  176 
Total quality assessment scores ranged from 15-25 (Table 3), and no study was 177 
excluded based on the results of the quality assessment.  Only seven articles reported adverse 178 
events,
31, 33-34, 37-38, 40-41




 six reported compliance with interventions,
35-40
 and one included a power calculation to 180 
determine sample size.
41
 Due to the nature of the interventions, none of the studies blinded 181 
participants to treatment allocation.  182 
 183 
Table 3 Near here 184 
 185 
Sample characteristics  186 
Study sample sizes ranged from 6-111 participants, and overall 474 participants were 187 
included, 325 of which were allocated to receive an intervention, and 149 to a control 188 
condition. Expanded Disability Status Scale (EDSS) scores of study samples ranged from 189 
1.5-9, and 12 articles reported participants with EDSS > 6.
29-35, 37-41
 Only one study used a 190 
pre-defined level for moderate-severe fatigue (Fatigue Severity Scale (FSS) ≥4) as an 191 
inclusion criterion for participant recruitment.
33




Outcome measures 194 
There were seven self-reported outcome measures used across the included articles to 195 
measure the impact and/or severity of fatigue – the most commonly used were the FSS 196 
(n=4),
32, 38-39, 41
 and the Modified Fatigue Impact Scale (MFIS) (n=4).
34-36, 40
 In addition, 197 
studies also used the Fatigue Impact Scale (FIS),
31, 33
 MS-Related Symptom Checklist 198 
(fatigue subscale),
30
 Fatigue Scale for Motor and Cognitive functions (FSMC),
37
 Medical 199 
Outcomes Study 36-Item Short Form Survey (SF-36) vitality subscale,
29, 41
 and MS Quality 200 
of Life 54 (MS QoL-54) energy subscale.
35
 Of the 13 included articles, 2 stated that fatigue 201 
was the primary outcome of investigation,
30, 33
 and in the remaining 11 fatigue was a 202 










 temporal measures of gait,
41









Interventions  207 






 and two behavioural interventions
33, 39
 were described by the 13 209 
included articles.  210 
Of the eight exercise interventions, four were classified as aerobic exercise,
35-37, 40
 one 211 
as combined exercise,
34
 one as task-orientated exercise,
41
 and two as other exercise.
32, 38
 212 
Various modes of exercise were used across the four trials of aerobic exercise: one used arm 213 
ergometry;
37
 two used body-weight supported treadmill training;
35, 40
 one used recumbent 214 
stepping;
40
 and Briken et al used arm ergometry, cycling, and rowing.
36
 Most interventions 215 
were performed at moderate intensity, and were progressed through increasing the duration of 216 
training; however, the study by Skjerbaek et al implemented a high intensity interval training 217 
12 
 
protocol involving three minute intervals working at a heart rate corresponding to 65-75% 218 
VO2peak.
37
 In addition to aerobic exercise, the combined exercise intervention described by 219 
Roehrs and Karst incorporated elements of upper and lower limb resistance exercises, and 220 
was delivered in a pool by physical therapy students.
34 
221 
The study by Straudi et al was characterised as task-orientated exercise, as the 222 
intervention aimed to improve temporal gait parameters by using a robotic assisted gait 223 
orthosis in conjunction with body-weight supported treadmill training.
41
 The two other 224 
exercise interventions involved seated Pilates,
38
 and inspiratory muscle training.
32
 The seated 225 
Pilates intervention was delivered by a qualified Pilates instructor, and incorporated elements 226 
of core and upper limb strengthening with a daily home exercise program.
38
 Inspiratory 227 
muscle training followed a self-management program of inspiratory muscle resistance 228 




The two behavioural intervention studies involved mindfulness,
39
 and energy 231 
conservation management.
33
 The mindfulness intervention was delivered, via a group-based 232 
video conference, by a health psychologist. The content involved components of the 233 
Mindfulness-based Stress Reduction programme with additional cognitive therapy exercises 234 
and ‘homework’ tasks. The energy conservation intervention was delivered face-to-face in a 235 
group by occupational therapists, and involved education regarding optimum energy use to 236 
minimise the impact of fatigue through re-structuring or altering activities of daily living 237 
following Packer’s energy conservation course.  238 
Rehabilitation interventions were delivered by a multidisciplinary team consisting of 239 
physiotherapists, occupational therapists, and support services in an outpatient setting, and 240 
treatments were individualised to each participant.
29-31
 In the study by Di Fabio et al., 241 
13 
 
participants received five hours of rehabilitation one day per week which consisted of 242 
physiotherapy (gait, transfer and balance training, endurance training, range of movement 243 
exercises), occupational therapy to maintain upper limb use during activities of daily living 244 
and enhance communication skills, and support services (support groups, social work, 245 
recreation activities, falls prevention programmes, seating clinics, and nutritional 246 
information).
29-30
 The intervention delivered by Patti et al. consisted of one hour of 247 
physiotherapy treatment five days per week, 30 minutes of occupational therapy and speech 248 
therapy twice per week, and support sessions on symptom self-management and goal 249 
setting.
31 





Effectiveness of exercise interventions 253 
Of the studies investigating aerobic exercise interventions, Skjerbaek et al. reported 254 
that, although FSMC scores improved in the exercise group post-intervention (mean 255 
difference = -2.2 ± 8.7), there was no significant difference between the exercise and control 256 
groups over time.
37
 Similarly, Pilutti et al. and Pilutti et al. reported non-significant 257 




 However, Pilutti et al. found statistically significant changes in MSQoL-54 energy subscale 259 
post-intervention (p=0.01).
35
 The studies by Pilutti et al., Skjerbaek et al., and Pilutti et al. 260 




 In contrast, Briken et al. investigated three aerobic exercise interventions in a larger 262 
population (n=47) of participants with moderate disability (EDSS: 4-6), and reported that 263 
exercise significantly improved fatigue from baseline (p=0.019); however, only arm 264 
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ergometry demonstrated significant improvements in comparison to the control group 265 
(p=0.013).
36
  266 





 or inspiratory muscle training.
32
 In addition, there 268 
were no significant improvements in FSS post-intervention or at six week follow-up for those 269 
receiving task-orientated exercise interventions; however, SF-36 vitality subscale scores 270 
improved post-intervention for the group receiving robot-assisted gait training (p<0.01), but 271 
returned to baseline at six week follow-up.
41
  272 
 273 
Effectiveness of behavioural interventions 274 
In a non-randomised cross-over trial, Vanage et al. investigated the use of an energy 275 
conservation course and reported a significant improvement in FIS total and subscale scores 276 
post-intervention (effect size 0.89, p<0.01) which was maintained at eight week follow-up.
33
 277 
However, Bogosian et al. reported no significant difference in fatigue scores post-278 
intervention and at six week follow-up between the group receiving a mindfulness 279 
intervention and a wait-list control.
39
 In addition to the mode of intervention, differences in 280 
results between studies may be explained by study design as Vanage et al. recruited 281 
participants with clinically significant level of fatigue and used fatigue as a primary 282 
outcome,
33




Effectiveness of rehabilitation interventions  285 
Di Fabio et al. reported that fatigue scores (MS-Related Symptom Checklist) for those 286 
receiving 52-weeks multidisciplinary rehabilitation were significantly different post-287 
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intervention in comparison to wait-list controls (effect sizes 0.46 and -0.2 for the intervention 288 
and control group respectively).
30
 From the same study, Di Fabio et al. also reported that SF-289 
36 vitality subscales scores improved post-intervention for the group receiving rehabilitation 290 
(effect size 0.3), and that fatigue in the wait-list control group increased in severity (effect 291 
size -0.39).
29
 In Patti et al., those receiving 12-weeks outpatient rehabilitation demonstrated a 292 




Clinical significance of changes in fatigue 295 
Of the outcome measures reported, MCID has only been determined for the FIS within 296 
MS populations. When anchored to measures of health-related quality of life, FIS 297 
demonstrates a MCID of 10-20 points.
42
 Of the two included studies that used the FIS, both 298 
reported statistically significant improvements in fatigue post-intervention (mean difference 299 
of 18.8 ± 14.3 (p<0.001)
31
 and mean difference of 15.7 ± 25 (p<0.01)
33
). The mean change in 300 
FIS scores recorded by both studies is within the range of MCID reported for the FIS; 301 
however, both studies reported large standard deviations suggesting that these interventions 302 
may be clinically significant for only some participants.  303 
 304 
Discussion 305 
Overall, the evidence presented in this review is inconclusive regarding the use of 306 
exercise, behavioural, and rehabilitation interventions to manage the severity and impact of 307 
fatigue in progressive MS populations. However, the quality of evidence is generally weak 308 




Exercise interventions 311 
The evidence is inconclusive regarding the effectiveness of exercise as an intervention 312 
to reduce the severity and impact of fatigue in people with progressive MS. However, of the 313 
four studies that investigated aerobic exercise, all demonstrated improvement in fatigue 314 
impact post-intervention;
35-37, 40
 although, only Briken et al reported that changes in fatigue 315 
impact were statistically significant.
36
 The result of this review including studies of people 316 
with progressive MS is comparable with a similar review which reported that aerobic 317 
exercise improves fatigue in those with RRMS.
17
 However, the studies included in this 318 
current review had small sample sizes, and were underpowered to detect significant changes 319 
in fatigue. In addition, three of the studies included participants with high-levels of disability 320 
(EDSS≥6) which may have further influenced results as, to date, the positive evidence for the 321 
effect of exercise on fatigue has only been demonstrated in those with mild-moderate 322 
disability (EDSS≤5.5),17, 43 whereas varied effects are reported in those with higher levels of 323 
disability.
27
  324 
Comparing the effectiveness of aerobic exercise with other modes of exercise is 325 
limited by the small number of heterogeneous studies. Only four studies investigated forms of 326 
exercise other than aerobic – including aquatic therapy34 and inspiratory muscle training32 – 327 
and the evidence generally does not support the effectiveness of these interventions for 328 
reducing fatigue in progressive MS populations. Furthermore, none of the included studies 329 
investigated the use of resistance training – which has been demonstrated to improve fatigue 330 
in people with RRMS.
43
 Consequently, although this review highlights the potential 331 
effectiveness of aerobic exercise in fatigue management for people with progressive MS, 332 
there is insufficient evidence to determine whether this is the most effective mode of 333 
exercise.  334 
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The mechanisms through which exercise may attenuate fatigue symptoms are 335 
unknown. It is hypothesised that exercise may have a neuroprotective and neuroregenerative 336 
benefit through increasing neural growth factors which modulate structural and functional 337 
CNS changes associated with primary MS-related fatigue.
13
 In addition, exercise training can 338 
influence secondary fatigue mechanisms caused by deconditioning, sleep disorders, and 339 
depression through increasing aerobic capacity, improving sleep quality, and managing 340 
depression.
13
 Immunological biomarkers interferon-γ, tumour necrosis factor α, and 341 
interleukin-1 have also been associated with fatigue in MS,
44
 but may have limited relevance 342 
to those with progressive MS due to the absence of a marked inflammatory response.
45 
343 
Of the aerobic exercise interventions included, three were performed at moderate 344 
intensity for durations of between 30-45 minutes, 2-3 times per week.
35-36, 40
 While this dose 345 
of exercise is recommended for people with mild-moderate MS,
46
 there was no evidence of a 346 
dose-response relationship to suggest that this prescription is most effective in managing 347 
fatigue – particularly in progressive MS populations. Indeed, one trial investigated shorter 348 
duration, high-intensity aerobic exercise,
37
 which may hold potential in fatigue management 349 
through inducing greater improvements in aerobic capacity over a shorter time.
47
 Therefore, 350 
no conclusions regarding the optimum dose of exercise to manage fatigue in people with 351 
progressive MS can be generated from the evidence in this review.  352 
There is also limited evidence for the long-term effectiveness of exercise 353 
interventions. Only two studies conducted follow-up measurement, neither of which reported 354 




 Consequently, there is a need to evaluate the long-term effectiveness of exercise 356 
interventions to determine if improvements in fatigue are sustained after the intervention 357 
period.  358 
18 
 
Despite the limited evidence for the effectiveness of exercise intervention, most 359 
studies reported low attrition rates indicating acceptability of exercise interventions in 360 
progressive MS populations. In addition, some studies confirmed that exercise interventions 361 
were feasible in populations with higher levels of disability associated with progressive MS, 362 
which is in line with evidence from previously published reviews.
27
  363 
 364 
Behavioural interventions 365 
As only two studies of behavioural interventions were included in this review it is not 366 
possible to reach any conclusion regarding their effectiveness in reducing the severity or 367 
impact of fatigue. Both studies investigated different forms of behavioural therapy 368 
interventions, and reported contrasting results regarding short and long term effectiveness. 369 
Vanage et al. reported that an 8-week energy conservation course significantly reduced 370 
fatigue impact immediately after the intervention period and at 8 week follow-up,
33
 which is 371 
comparable with previous evidence from predominantly RRMS populations.
15
  372 
In contrast, Bogosian et al. reported no significant difference in fatigue severity post-373 
intervention or at 4 weeks follow-up between those receiving a mindfulness intervention and 374 
a waitlist control.
39
 Mindfulness is used in MS to manage somatic symptoms and improve 375 
health-related quality of life,
48
 and is recommended in the NICE guidelines as a strategy to 376 
manage fatigue.
14
 However, the mindfulness intervention implemented by Bogosian et al. 377 
was designed to manage distress not fatigue.
39
 Therefore, despite the association between 378 
mood disorders and fatigue,
9, 49-51
 the applicability of these findings to fatigue management is 379 
limited. In addition, the mindfulness sessions were delivered via video conference which, 380 
while accommodating those with severe mobility disabilities, may limit the social benefits 381 
reported during group based interventions delivered face-to-face.
33, 52




Rehabilitation interventions  384 
Although evidence from this review is positive regarding the effects rehabilitation on 385 
fatigue only 2 studies of rehabilitation interventions were included. Generally, rehabilitation 386 
interventions were individualised to each participant, goal-orientated, addressed functional 387 
performance, and were delivered by a multidisciplinary team. In both articles, changes in 388 
fatigue severity after 52-weeks of multidisciplinary rehabilitation were statistically 389 
significant, with moderate effect sizes reported for those receiving rehabilitation and 390 
worsening fatigue in the wait-list control group.
29-30
 However, as this study only included two 391 
points of outcome assessment (baseline and 52 weeks), the rate at which improvements in 392 
fatigue were accumulated cannot be observed. Patti et al. implemented a shorter duration, 393 
higher intensity intervention which demonstrated clinically significant improvements in 394 
fatigue impact for some participants post-intervention.
31
 Therefore, there is a need to 395 
determine the most effective duration of rehabilitation interventions.  396 
It is acknowledged that exercise and/or behavioural interventions can be delivered as 397 
components of rehabilitation. However, the rehabilitation interventions included in this 398 
review were multidisciplinary, and were differentiated from exercise and behavioural 399 
interventions alone as they contained additional treatment strategies – such as physiotherapy 400 
and occupational therapy to maintain physical function. Consequently, it was not possible to 401 
identify the effectiveness of each component part of rehabilitation – for example, the 402 
effectiveness of exercise delivered as part of rehabilitation. This information is essential to 403 




Limitations of the evidence  406 
There were several important limitations which impact upon the overall quality of 407 
evidence.  Firstly, only two studies used fatigue as a primary outcome measure,
30, 33
 and of 408 
these studies, only one recruited participants with clinically significant levels of fatigue 409 
(FSS≥4).33 Therefore, there is limited evidence of the effect of interventions specifically 410 
designed to manage fatigue in people with clinically significant levels of fatigue.  411 
In addition, seven different fatigue outcome measures were used in this review, 412 
limiting the ability to directly compare results between studies. Although a meta-analysis of 413 
exercise interventions demonstrated that the selection of fatigue outcome measure did not 414 
moderate the effect of interventions,
17
 there is a need for core fatigue outcome measures to 415 
enable pooling of statistical data for meta-analysis and comparison of effects between studies. 416 
In addition, MCID has only been determined for the FIS. Therefore, the MCID of the MFIS 417 
and FSS should be determined to establish the clinical significance of changes in both fatigue 418 
severity and impact. 419 
Finally, most studies were under-powered to detect significant changes in fatigue. In 420 
addition, due to the inclusion of quasi-experimental studies, several studies were unable to 421 
control for confounding variables which may have accounted for the heterogeneous treatment 422 
response reported within and between studies. Furthermore, adverse events and compliance 423 
to interventions were poorly reported across studies, limiting the ability to determine the 424 
safety and efficacy of interventions in clinical practice.  425 
 426 
Limitations of the review  427 
There were many other studies that investigated the effectiveness of fatigue 428 
management interventions in people with progressive MS; however, these studies were 429 
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excluded as the results for those with progressive MS could not be specifically identified. In 430 
addition, the overall quality of evidence in this review is limited by the inclusion of quasi-431 
experimental studies, which are less methodologically rigorous and introduce risk of selection 432 
bias. Furthermore, due to the inclusion of quasi-experimental studies and heterogeneity in 433 
outcome measures and interventions used between studies, it was not feasible to conduct a 434 
meta-analysis and results were generated by narrative synthesis.   435 
 436 
Conclusion 437 
There is insufficient evidence regarding the effectiveness of non-pharmacological 438 
interventions in reducing the impact and severity of fatigue in people with progressive MS. 439 
This review suggests that exercise, behavioural interventions, and rehabilitation may have the 440 
potential to manage fatigue. However future, adequately powered, rigorous trials of 441 
interventions to manage fatigue in populations with severe levels of fatigue are required. In 442 
addition, future studies should clearly identify the specific results for people with progressive 443 
MS due to the limited available evidence for this population.  444 
 445 
Conflict of Interest: None 446 
Financial Support: This research did not receive any specific grant from funding agencies 447 




1) Lerdal A, Celius EG, Krupp L, Dahl AA. A prospective study of patterns of fatigue in 450 
multiple sclerosis. Eur J Neurol. 2007;14(12):1338-1343. 451 
2) Hadjimichael O, Vollmer T, Oleen-Burkey M, North American Research Committee 452 
on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: the North 453 
American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health 454 
Qual Life Outcomes. 2008;6(100):1-11. 455 
3) Zajicek JP, Ingram WM, Vickery J, Creanor S, Wright DE, Hobart JC. Patient-456 
orientated longitudinal study of multiple sclerosis in south west England (The South 457 
West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline 458 
characteristics of cohort. BMC Neurol. 2010;10(88):1-11. 459 
4) Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: The impact 460 
of fatigue and depression. J Neurol Sci. 2002;205(1):51-58. 461 
5) Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and 462 
management. Mult Scler. 2003;9(3):219-227. 463 
6) Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP. 464 
Demographic and clinical factors associated with changes in employment in multiple 465 
sclerosis. Mult Scler. 2013;19(12):1647-1654. 466 
7) Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple 467 
sclerosis: Evidence-based management strategies for fatigue in multiple sclerosis. 468 
Washington D.C.: Paralyzed Veterans of America. 1998. 469 




9) Johansson S, Ytterberg C, Hillert J, Widen Holmqvist L, von Koch L. A longitudinal 472 
study of variations in and predictors of fatigue in multiple sclerosis. J Neurol 473 
Neurosurg Psychiatry. 2008;79(4):454-457. 474 
10) Mills RJ, Young CA. The relationship between fatigue and other clinical features of 475 
multiple sclerosis. Mult Scler. 2011;17(5):604-612. 476 
11) Kos D, Kerckhofs E, Nagels G, D'hooghe MB, Ilsbroukx S. Origin of Fatigue in 477 
Multiple Sclerosis: Review of the Literature. Neurorehabil Neural Repair. 478 
2008;22(1):91-100. 479 
12) Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis — A brief 480 
review. J Neurol Sci. 2012;323(1-2):9-15 481 
13) Langeskov-Christensen M, Bisson EJ, Finlayson ML, Dalgas U. Potential 482 
pathophysiological pathways that can explain the positive effects of exercise on 483 
fatigue in multiple sclerosis: A scoping review. J Neurol Sci. 2017;373:307-320. 484 
14) National Institute for Health and Care Excellence. Multiple sclerosis in adults: 485 
management. National Institute for Health and Care Excellence. 2014. Retrieved from 486 
https://www.nice.org.uk/guidance/cg186 487 
15) Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. 488 
Effectiveness of energy conservation treatment in reducing fatigue in multiple 489 
sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil. 490 
2013;94(7):1360-1376. 491 
16) Asano M, Finlayson ML. Meta-analysis of three different types of fatigue 492 
management interventions for people with multiple sclerosis: exercise, education, and 493 
medication. Mult Scler Int. 2014; 2014:1-12. 494 
24 
 
17) Heine M, van dP, Rietberg MB, van Wegen E,E.H., Kwakkel G. Exercise therapy for 495 
fatigue in multiple sclerosis. Cochrane database syst rev 2015;9:CD009956. 496 
18) van den Akker LE, Beckerman H, Collette EH, Eijssen IC, Dekker J, de Groot V. 497 
Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients 498 
with multiple sclerosis: A systematic review and meta-analysis. J Psychosom Res. 499 
2016;90:33-42. 500 
19) Fox R, Thompson A, Baker D, Baneke P, Brown D, Browne P, et al. Setting a 501 
research agenda for progressive multiple sclerosis: The International Collaborative on 502 
Progressive MS. Mult Scler. 2012;18(11):1534-1540. 503 
20) Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical 504 
fitness: definitions and distinctions for health-related research. Public Health Rep. 505 
1985;100(2):126-131. 506 
21) World Health Organisation. World report on disability 2011. World Health 507 
Organisation. 2011. Retrieved from 508 
http://www.who.int/disabilities/world_report/2011/en/ 509 
22) Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: 510 
updated guidelines for reporting parallel group randomised trials. BMJ. 511 
2010;340:c332. 512 
23) Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better 513 
reporting of interventions: template for intervention description and replication 514 
(TIDieR) checklist and guide. BMJ. 2014;348:1-12. 515 
25 
 
24) Downs SH, Black N. The feasibility of creating a checklist for the assessment of the 516 
methodological quality both of randomised and non-randomised studies of health care 517 
interventions. J Epidemiol Community Health. 1998;52(6):377. 518 
25) Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating 519 
non-randomised intervention studies. Health Technol Assess. 2003;7(27):1-186. 520 
26) Latimer-Cheung AE, Pilutti LA, Hicks AL, Martin Ginis KA, Fenuta AM, 521 
MacKibbon KA, et al. Effects of exercise training on fitness, mobility, fatigue, and 522 
health-related quality of life among adults with multiple sclerosis: a systematic review 523 
to inform guideline development. Arch Phys Med Rehabil. 2013;94(9):1800-1828. 524 
27) Edwards T, Pilutti LA. The effect of exercise training in adults with multiple sclerosis 525 
with severe mobility disability: A systematic review and future research directions. 526 
Mult Scler Relat Disord. 2017;16:31-39. 527 
28) Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting 528 
items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 529 
2009;6(7):1-6. 530 
29) Di Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for 531 
patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther. 532 
1997;77(12):1704-1716. 533 
30) Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient 534 
rehabilitation: its influence on symptom frequency, fatigue, and functional status for 535 




31) Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F, et al. Effects of a 538 
short outpatient rehabilitation treatment on disability of multiple sclerosis patients -- a 539 
randomised controlled trial. J Neurol. 2003;250(7):861-866. 540 
32) Klefbeck B, Nedjad JH. Effect of inspiratory muscle training in patients with multiple 541 
sclerosis. Arch Phys Med Rehabil. 2003;84(7):994-999. 542 
33) Vanage S, Gilbertson K, Mathiowetz V. Effects of an energy conservation course on 543 
fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther. 544 
2003;57(3):315-323. 545 
34) Roehrs TG, Karst GM. Effects of an aquatics exercise program on quality of life 546 
measures for individuals with progressive multiple sclerosis. J Neurol Phys Ther. 547 
2004;28(2):63-71. 548 
35) Pilutti LA, Lelli DA, Paulseth JE, Crome M, Jiang S, Rathbone MP, et al. Effects of 549 
12 weeks of supported treadmill training on functional ability and quality of life in 550 
progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil. 2011;92(1):31-551 
36. 552 
36) Briken S, Gold SM, Patra S, Vettorazzi E, Harbs D, Tallner A, et al. Effects of 553 
exercise on fitness and cognition in progressive MS: a randomized, controlled pilot 554 
trial. Mult Scler. 2014;20(3):382-390. 555 
37) Skjerbaek AG, Naesby M, Lutzen K, Moller AB, Jensen E, Lamers I, et al. Endurance 556 
training is feasible in severely disabled patients with progressive multiple sclerosis. 557 
Mult Scler. 2014;20(5):627-630. 558 
27 
 
38) van d L, Bulley C, Geneen LJ, Hooper JE, Cowan P, Mercer TH. Pilates for people 559 
with multiple sclerosis who use a wheelchair: feasibility, efficacy and participant 560 
experiences. Disabil Rehabil. 2014;36(11-13):932-939. 561 
39) Bogosian A, Chadwick P, Windgassen S, Norton S, McCrone P, Mosweu I, et al. 562 
Distress improves after mindfulness training for progressive MS: A pilot randomised 563 
trial. Mult Scler. 2015;21(9):1184-1194. 564 
40) Pilutti LA, Paulseth JE, Dove C, Jiang S, Rathbone MP, Hicks AL. Exercise training 565 
in progressive multiple sclerosis: a comparison of recumbent stepping and body 566 
weight-supported treadmill training. Int J MS Care. 2016;18(5):221-229. 567 
41) Straudi S, Fanciullacci C, Martinuzzi C, Pavarelli C, Rossi B, Chisari C, et al. The 568 
effects of robot-assisted gait training in progressive multiple sclerosis: a randomized 569 
controlled trial. Mult Scler. 2016;22(3):373-384. 570 
42) Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD. A novel approach to 571 
estimate the minimally important difference for the Fatigue Impact Scale in multiple 572 
sclerosis patients. Qual Life Res. 2010;19(9):1349-1358. 573 
43) Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ. Effects of exercise 574 
training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med. 575 
2013;75(6):575-580. 576 
44) Patejdl R, Penner IK, Noack TK, Zettl UK. Multiple sclerosis and fatigue: A review 577 
on the contribution of inflammation and immune-mediated neurodegeneration. 578 
Autoimmun Rev. 2016;15(3):210-220. 579 
28 
 
45) Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: 580 
prospects for disease therapy, repair, and restoration of function. Lancet. 581 
2017;389(10076):1357-1366. 582 
46) Latimer-Cheung AE, Ginis KAM, Hicks AL, Motl RW, Pilutti LA, Duggan M, et al. 583 
Development of evidence-informed physical activity guidelines for adults with 584 
multiple sclerosis. Arch Phys Med Rehabil. 2013;94(9):1829-1836. 585 
47) Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: 586 
recommendations for the application of resistance-, endurance- and combined 587 
training. Mult Scler. 2008;14(1):35-53. 588 
48) Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S. Mindfulness based 589 
interventions in multiple sclerosis--a systematic review. BMC Neurol. 2014;14:1-9. 590 
49) Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Fatigue in multiple 591 
sclerosis persists over time: a longitudinal study. J Neurol. 2006;253(11):1466-1470. 592 
50) Brown RF, Valpiani EM, Tennant CC, Dunn SM, Sharrock M, Hodgkinson S, et al. 593 
Longitudinal assessment of anxiety, depression, and fatigue in people with multiple 594 
sclerosis. Psychol Psychother. 2009;82:41-56. 595 
51) Wood B, van der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence 596 
and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. 597 
Mult Scler. 2013;19(2):217-224. 598 
52) Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized 599 
controlled trial of an energy conservation course for persons with multiple sclerosis. 600 
Mult Scler. 2005;11(5):592-601.  601 
29 
 
Figure Legend 602 









Table 1 Definition of included interventions 607 
Intervention  Definition 
Exercise  Exercise was defined as “planned, structured and repetitive bodily movement 
carried out to improve or maintain one or more components of physical fitness” 
– this definition included conventional aerobic and/or resistance based exercise, 
task orientated exercise, and alternative exercise methods.
20 
  
Behavioural  For behavioural interventions, studies must state or describe a behavioural 
therapy intervention which aimed to facilitate behavioural or attitudinal 
changes. Common behavioural interventions are cognitive behavioural therapy, 
mindfulness, or interventions aimed at modifying behaviour specifically in 




Rehabilitation Rehabilitation interventions included treatment strategies that aimed to maintain 
or improve current level of function, or prevent the loss of function, and were 
delivered in a hospital (in-patient or out-patient) or community based setting by 
a multi-disciplinary team of relevant health-care professionals.
21
 Exercise 
and/or behavioural interventions were classified as rehabilitation interventions 
if additional treatment components were delivered alongside these 
interventions.  
 608 
  609 
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Table 2 Study, participant, intervention, and outcome details, and main findings from included articles 
Author, date, 
and design 
Sample details Intervention type, mode of delivery, duration, 






Main findings*   






N= 44 (all progressive MS) 
SPMS, n (%): NR   
PPMS, n (%): NR 
EDSS range, 5-8 
Sex (m/f), n: 6/25 
Dropout, n (%): 13 (30%) 
Outpatient rehabilitation program (n=19): delivered in a 
MS treatment centre by physical therapists, occupational 
therapists, and supportive services  
Waiting list control (n=25) 




0, 52 weeks  
SF-36 (vitality subscale) 
Within group (effect size): I=0.3; C=-0.39 
 
 
      






N= 46 (all progressive MS) 
SPMS, n (%): NR 
PPMS, n (%): NR 
EDSS range, 5-8 
Sex (m/f), n: 12/34 
Dropout, n (%): 13 (28%) 
Outpatient rehabilitation program (n=20): delivered in a 
MS treatment centre by physical therapists, occupational 
therapists, and supportive services  
Waiting list control (n=26) 






0, 52 weeks 
MS-Related Symptom Checklist fatigue subscale 
Baseline†: I=2.9 (0.32); C=3.2 (0.25) 
Within group (effect size): I=0.46; C=-0.20 
Between groups: P=0.004 
      
Patti et al.,31 
2002, RCT 
Rehabilitation 
N= 111 (all progressive 
MS) 
SPMS, n (%):  NR 
PPMS, n (%):  NR 
EDSS range, 4-8 
Sex (m/f), n: 47/64 
Dropout, n (%): 13 (12%) 
Outpatient rehabilitation program (n=58): 6 weeks, 6 
days/week, followed by 6 weeks home-exercise. 
Rehabilitation included physiotherapy, occupational 
therapy, speech therapy, supportive treatments, group 
physiotherapy  
Home-exercise control (n=53): 12 weeks of home-
exercise program 
FIS (secondary) 
0, 6, 12 weeks 
FIS 
Baseline: I= 116.8±40.9, C=127±36 
12 weeks (MD): I=-18.8±14.3, P<0.001; C=0.6±0.9, 
P>0.05 
Between groups: P <0.001 
      
Klefbeck et al.,32 
2003, RCT 
Exercise – other 
N= 16 (all progressive MS) 
SPMS, n (%):  NR 
PPMS, n (%):  NR 
EDSS range, 6.5-9.5 
Sex (m/f), n: 9/6 
Dropout, n (%): 1 (6%) 
Inspiratory muscle training (n=8): 10 weeks, 10 minutes 
training twice every other day consisting of 3 sets of 10 
loaded inspirations using Threshold IMT device with 1 
minute rest between sets.  
Control (n=8): Usual physiotherapy care 
FSS (secondary) 
0, 10, 14 weeks 
FSS 
Baseline: I= 5±1.3, C=4.5±1.3 
Between groups (10 weeks): P>0.05 
      






N= 37 (all progressive MS) 
SPMS, n (%):  NR 
PPMS, n (%):  NR 
EDSS, ≥5 
Sex (m/f), n: 8/29 
Dropout, n (%): 9 (24%) 
Group based (3-8 participants per group) energy 
conservation course modified for those with increased 
disability, delivered by occupational therapists in a 
rehabilitation centre 
Group A: intervention followed by control (n=21), Group 
B: control followed by intervention (n=16) 




8 week follow-up 
FIS (total) 
Pre/post-intervention: 



































      








N= 31 (all progressive MS) 
SPMS, n (%):  NR 
PPMS, n (%):  NR 
EDSS range, 1.5-8 
Sex (m/f), n: 7/12 
Dropout, n (%): 12 (39%) 
Aquatic exercise intervention (n=31): endurance, 
strengthening, and balance exercises delivered in a pool 
by physical therapy students, exercises modified 
depending upon functional ability 
12 weeks, 2 session/week, 60 minutes 
MFIS (secondary)  
0, 12 weeks 
MFIS 
Baseline: 48.7±12.1 
Post-intervention (final value): 43.5±15 
Pre/post-intervention: P=0.035 
      







SPMS, n (%): 1 (17%) 
PPMS, n (%): 5 (83%) 
EDSS range, 5.5-8 
Sex (m/f), n: 2/4 
Dropout, n (%): 0 (0%) 
Body-weight supported treadmill training (n=6) 
Percentage body weight support and treadmill speed 
individualised to each participant in relation to posture 
and comfort when walking 
Training progressed initially by increasing treadmill 
speed followed by reducing body weight support 










13.3±20.96, Effect size 







5.9±9.27, Effect size 







6.8±9.46, Effect size 







0.7±3.08, Effect size 








size (95% CI)=0.93 
(9.28, 29.39), P=0.01 
      






SPMS, n (%): 31 (74%) 
PPMS, n (%): 11 (26%) 
EDSS range, 4-6 
Sex (m/f), n: 18/24 
Dropout, n (%): 5 (11%) 
 
rowing (n=12), cycling (n=12), wait-list control (n=11) 
Intervention delivered in a medical centre by a 
physiotherapist. Training intensity tailored to each 
participant depending upon performance during 
submaximal aerobic fitness assessment 
8-10 weeks, 2-3 sessions/week , 15-45 minutes 
(Secondary) 
0, 10 weeks  
Baseline: Arm ergometry: 45.00±14.73, Rowing: 
35.27±13.86, Cycling: 35.27±13.86, C: 38.00±15.15 
 
Between group: Arm ergometry vs C: (P=0.013), 
Rowing vs C: (P>0.05), Cycling vs C: (P>0.05), All 
interventions vs C: (P=0.019) 
      





SPMS, n (%): 8 (73%) 
PPMS, n (%): 3 (27%) 
EDSS range, 6.5-8 
Sex (m/f), n: 3/8 
Dropout, n (%): 1 (9%) 
Upper body endurance training (n=6): Standard care plus 
10 sessions of upper limb arm ergometry over 4 weeks, 
consisting of 6 x 3 minute intervals at target heart rate 
corresponding to 65-75% of VO2peakControl (n=5): 4 
weeks of individualised multi-disciplinary inpatient 




0, 4 weeks 
FSMC (total) 
Baseline: I=65±18.5, C= 
53±16.3 
Within group (MD): I=-
2.2±8.7, C=-2.6±7.9 
Between groups: P=0.94 
 
FSMC (motor subscale) 
Baseline: I=36±7.9, 
C=29±8 
Within group (MD): I=-
2.8±5.6, C=-2±5.3 






Within group (MD): 
I=0.6±3.6, C=-0.6±2.7 
Between groups: P=0.57 
      





Exercise – other  
N= 15 (all progressive MS) 
SPMS, n (%):  NR 
PPMS, n (%):  NR 
EDSS range, 7-8 
Sex (m/f), n: 7/8 
Dropout, n (%): 1 (7%) 
Seated Pilates (n=15) exercises focused on core 
strengthening, with elements of upper limb strengthening 
exercises and a home-exercise program to be performed 
15 minutes daily 
Delivered by a qualified Pilates instructor at 2 
community centres 
Weeks 1-6: 2 session/week, 60 minutes 
Weeks 7-12: 1 session/week, 60 minutes 
FSS (secondary) 
0, 6, 12 weeks 
FSS 
Baseline: 5.2±1.3 
Week 6 (final value)=4.7±1.6  
Week 12 (final value)=4.9±1.7 
Baseline, week 6: P=0.132  
Baseline, week 12: P=0.295 
      




SPMS, n (%): 23 (58%) 
PPMS, n (%): 17 (42%) 
EDSS mean (SD), 6.5 (1.5) 
Sex (m/f), n: 18/22 
Dropout, n (%): 7 (18%) 
 
Mindfulness intervention to manage distress 
Group-based video conference adapted from 
Mindfulness-Based Cognitive Therapy course book 
(n=19), wait-list control (n=21) 
Intervention delivered to groups of 5 people by health 
psychologist with training in delivering mindfulness 
sessions. 8 weeks, 1 session/week, 60 minutes  
FSS (Secondary) 
0, 8, 12 weeks 
FSS 
Baseline:  
I: 39.91±14.45, C: 48.29±12.24 
Between groups post-test: MD=-4.20, Effect size 
(95% CI)=-0.3 (-9.84, 1.45), P=0.145 
Between groups 3-months: MD=-4.07, Effect size 
(95% CI)=-0.29 (-10.69, 2.56), P=0.302 
      







SPMS, n (%): 8 (66%) 
PPMS, n (%): 4 (33%) 
EDSS range, 6-8 
Sex (m/f), n: 6/6 
Dropout, n (%): 2 (17%) 
Total-body recumbent stepper training (TBRST) (n=6), 
Body-weight supported treadmill training (BWSTT) 
(n=6) 
Participants instructed to exercise at 3-5 Borg rating of 
perceived effort (10-point scale) 

















Within groups (effect 































      
Straudi et al.,41 
2016, RCT 
Exercise – task 
orientated 
N= 58 
SPMS, n (%): 36 (69%) 
PPMS, n (%): 16 (31%) 
EDSS range, 6-7 
Sex (m/f), n: 18/34 
Dropout, n (%): 9 (16%) 
Robot-assisted gait training (n=30): body-weight 
supported treadmill training with robotic-driven gait 
orthosis, starting with 100% guidance from orthosis and 
50% body weight support, and 10% adjustments were 
made to both settings as training progressed. Treadmill 
speed varied between 0.1-3 km/h  
Conventional walking therapy (n=28): lower limb muscle 
stretching and strengthening, motor co-ordination, gait, 
and balance exercises 










MD (vs baseline):  






























Abbreviations: C, Control group; EDSS, Expanded Disability Status Scale; FIS, Fatigue Impact Scale; FSS, Fatigue Severity Scale; FSMC, Fatigue Scale for Motor and Cognitive functions; I, Intervention group; MD, 
Mean difference; MFIS, Modified Fatigue Impact Scale; MS, Multiple Sclerosis; MS QoL, Multiple Sclerosis Quality of Life Scale; NR, not reported; PPMS, primary progressive multiple sclerosis; RCT, randomised 
controlled trial; SF-36, Medical Outcomes Study 36-Item Short Form Survey; SPMS, secondary progressive multiple sclerosis; VO2peak, peak oxygen uptake 
* Descriptive baseline and final values presented as mean ± SD unless stated otherwise  




Table 3 Downs and Black Checklist scores for included studies  
Authors Downs & Black Checklist item* Total 





















































1 1 1 1 2 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 0 1 1 1 1 1 25 
Notes: 2, criterion fully met (item 5); 1, criterion met or partially met (item 5); 0, criterion not met 
*Abbreviated Downs and Black checklist item description: 1, hypothesis/aims/objectives reported; 2, main outcome measures reported; 3, participant characteristics reported; 4, intervention 
details reported; 5, principal confounders reported; 6, main findings reported; 7, variability in main outcomes reported; 8, adverse events reported; 9, loss to follow-up reported; 10, probability 
values reported; 11, source population representative of entire population; 12, study population representative of source population; 13, study setting representative of usual care; 14, participants 
blinded to intervention; 15, outcome assessors blinded; 16, no retrospective sub-group analysis; 17, analysis adjusts for different lengths of follow-up of participants; 18, statistical tests are 
appropriate; 19, reliable compliance with intervention; 20, outcome measures are valid and reliable; 21, recruitment of study groups from same population; 22, recruitment of participants over 
36 
 
same time period; 23, randomisation of participants; 24, allocation concealment; 25, adjustment for confounding variables in main analysis; 26, adjustment for loss to follow-up in main analysis; 





Supplementary table 1 Search strategies for electronic databases 
Database Search Terms 
CINAHL (via 
EBSCOhost) 
1. (“Multiple sclerosis” or MS) 
2. (MH "Exercise+") or (MH "Resistance Training") or (MH 
"Therapeutic Exercise+") or (MH "Exercise Positions+") or (MH 
"Group Exercise") or (MH "Aerobic Exercises+") 
3. (Exercise or  "Resistance Training" or "Therapeutic Exercise" or  
"Exercise Position*" or  "Group Exercise" or "Aerobic Exercise*") 
4. (MH "Cognitive Therapy+") or (MH "Behavior Therapy+") 
5. ("cognitive therap*" or "behav* therap*" or "cognitive behavio?ral 
therapy" or CBT or "psychotherapeutic treatment*" or 
mindfulness) 
6. ("energy manag*" or "energy conserv*" or "energy saving" or 
"fatigue manag*" or "managing fatigue" or pacing) 
7. (MH "Rehabilitation+") or (MH "Rehabilitation Centers+") or 
rehab* 
8. (MH "Fatigue+") or (fatigue or "physical fatigue" or "mental 
fatigue" or "central fatigue" or "fatigue impact") 
9. 2 or 3 or 4 or 5 or 6 or 7  
10. 1 and 8 and 9  
  
Cochrane Library 1. (("Multiple sclerosis" or MS) near/2 progressive) 
2. (MeSH descriptor: [Exercise] explode all trees)or (MeSh 
descriptor: [Exercise therapy] explode all trees) or (Mesh 
descriptor: [Resistance training] explode all trees) or (MeSH 
descriptor: [Exercise movement techniques] explode all trees) or 
(MeSH descriptor: [Plyometric exercise] explode all trees) 
3. (exercise or “exercise therap*” or “exercise movement 
technique*” or “resistance training” or “aerobic exercise*”) 
4. ("energy manag*" or "energy conserv*" or "energy saving" or 
"fatigue manag*" or "managing fatigue" or pacing) 
5. (MeSH descriptor: [behavior therapy] explode all trees) or (MeSH 
descriptor: [cognitive therapy] explode all trees) 
6. ("cognitive therap*" or "behav* therap*" or "cognitive behavio?ral 
therapy" or CBT or "psychotherapeutic treatment*" or 
mindfulness) 
7. (MeSH descriptor: [Rehabilitation] explode all trees) or (MeSH 
descriptor: [Rehabilitation Centers] explode all trees) or rehab* 
8. (fatigue or "physical fatigue" or "mental fatigue" or "central 
fatigue" or "fatigue impact") 
9. 2 or 3 or 4 or 5 or 6 or 7  
10. 1 and 8 and 9  
  
MEDLINE (via Ovid) 1. (("Multiple sclerosis" or MS) adj2 progressive).mp. 
2. exp Exercise/ or exp Exercise therapy/ or exp Resistance training/ 
or exp Exercise movement techniques/ or exp Plyometric exercise 
3. (exercise or “exercise therap*” or “exercise movement 
technique*” or “resistance training” or “aerobic exercise*”).mp. 
4. ("energy manag*" or "energy conserv*" or "energy saving" or 
"fatigue manag*" or "managing fatigue" or pacing).mp. 
5. exp behavior therapy/ or exp cognitive therapy/ 
38 
 
6. ("cognitive therap*" or "behav* therap*" or "cognitive behavio?ral 
therapy" or CBT or "psychotherapeutic treatment*" or 
mindfulness).mp. 
7. exp Rehabilitation/ or rehab*.mp. or exp Rehabilitation Centers/ 
8. (fatigue or "physical fatigue" or "mental fatigue" or "central 
fatigue" or "fatigue impact").mp. 
9. 2 or 3 or 4 or 5 or 6 or 7  
10. 1 and 8 and 9  
  
PEDro 1. Progressive AND multiple AND sclerosis  
  
ProQuest (Health & 
Medical Collection, 
Nursing & Allied 
Health Database, 
PsycINFO) 
1. (("Multiple sclerosis" or MS) NEAR/2 progressive) 
2. (exercise or “exercise therap*” or “exercise movement 
technique*” or “resistance training” or “aerobic exercise*”) 
3. ("energy manag*" or "energy conserv*" or "energy saving" or 
"fatigue manag*" or "managing fatigue" or pacing) 
4.  ("cognitive therap*" or "behav* therap*" or "cognitive 
behavio?ral therapy" or CBT or "psychotherapeutic treatment*" or 
mindfulness) 
5. (Rehab* or “rehabilitation centres”) 
6. (fatigue or "physical fatigue" or "mental fatigue" or "central 
fatigue" or "fatigue impact") 
7. 2 or 3 or 4 or 5  
8. 1 and  6 and  7  
  
Web of Science Core 
Collections 
1. (("Multiple sclerosis" or MS) Near/2 progressive) 
2. (exercise or “exercise therap*” or “exercise movement 
technique*” or “resistance training” or “aerobic exercise*”) 
3. ("energy manag*" or "energy conserv*" or "energy saving" or 
"fatigue manag*" or "managing fatigue" or pacing) 
4.  ("cognitive therap*" or "behav* therap*" or "cognitive 
behavio?ral therapy" or CBT or "psychotherapeutic treatment*" or 
mindfulness) 
5. (Rehab* or “rehabilitation centres”) 
6. (fatigue or "physical fatigue" or "mental fatigue" or "central 
fatigue" or "fatigue impact") 
7. 2 or 3 or 4 or 5  
8. 1 and  6 and  7 
 
 
